Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Lenka Oplustil O’Connor, Stuart L. Rulten, Aaron Cranston, et al.
Cancer Research (2016) Vol. 76, Iss. 20, pp. 6084-6094
Open Access | Times Cited: 82

Showing 1-25 of 82 citing articles:

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier, Mark J. O’Connor, Johann S. de Bono
Science Translational Medicine (2016) Vol. 8, Iss. 362
Closed Access | Times Cited: 652
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Sylvie M. Noordermeer, Haico van Attikum
Trends in Cell Biology (2019) Vol. 29, Iss. 10, pp. 820-834
Open Access | Times Cited: 374
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
Ewa Gogola, Alexandra A. Duarte, Julian R. de Ruiter, et al.
Cancer Cell (2018) Vol. 33, Iss. 6, pp. 1078-1093.e12
Open Access | Times Cited: 301
DNA Repair Pathways in Cancer Therapy and Resistance
Lanya Li, Yidi Guan, Xisha Chen, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 283
PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation
George E. Ronson, Ann Liza Piberger, Martin R. Higgs, et al.
Nature Communications (2018) Vol. 9, Iss. 1
Open Access | Times Cited: 179
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley, Judith Balmañà, Jonathan A. Ledermann, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 25, pp. 2257-2269
Open Access | Times Cited: 172
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
Marco Barazas, Stefano Annunziato, Stephen J. Pettitt, et al.
Cell Reports (2018) Vol. 23, Iss. 7, pp. 2107-2118
Open Access | Times Cited: 136
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Man Yee Keung, Yanyuan Wu, Jaydutt V. Vadgama
Journal of Clinical Medicine (2019) Vol. 8, Iss. 4, pp. 435-435
Open Access | Times Cited: 136
Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Sonia Iyer, Shuang Zhang, Simge Yucel, et al.
Cancer Discovery (2020) Vol. 11, Iss. 2, pp. 384-407
Open Access | Times Cited: 98
The SARS-CoV-2 Nsp3 macrodomain reverses PARP9/DTX3L-dependent ADP-ribosylation induced by interferon signaling
Lilian C. Russo, Rebeka Tomasin, Isaac de Araújo Matos, et al.
Journal of Biological Chemistry (2021) Vol. 297, Iss. 3, pp. 101041-101041
Open Access | Times Cited: 97
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 7, pp. 1690-1699
Open Access | Times Cited: 95
PET Imaging of PARP Expression Using 18F-Olaparib
Thomas C. Wilson, Mary‐Ann E. Xavier, James C. Knight, et al.
Journal of Nuclear Medicine (2018) Vol. 60, Iss. 4, pp. 504-510
Open Access | Times Cited: 86
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
Lotte van Beek, Éilís McClay, Saleha Patel, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5112-5112
Open Access | Times Cited: 68
PARP Inhibitors in Breast and Ovarian Cancer
Samuel Sherng Young Wang, Yeo Ee Jie, Sim Wey Cheng, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2357-2357
Open Access | Times Cited: 28
Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors
Jinhyuk Bhin, Mariana Paes Dias, Ewa Gogola, et al.
Cell Reports (2023) Vol. 42, Iss. 5, pp. 112538-112538
Open Access | Times Cited: 24
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas
Khyati Meghani, Walker Fuchs, Alexandre Detappe, et al.
Cell Reports (2018) Vol. 23, Iss. 1, pp. 100-111
Open Access | Times Cited: 67
Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
Desh Deepak Singh, Amna Parveen, Dharmendra Kumar Yadav
Biomedicines (2021) Vol. 9, Iss. 11, pp. 1512-1512
Open Access | Times Cited: 54
Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer
Ewa Gogola, Sven Rottenberg, Jos Jonkers
Annual Review of Cancer Biology (2018) Vol. 3, Iss. 1, pp. 235-254
Closed Access | Times Cited: 54
Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer
Grainne M. O’Kane, Ashton A. Connor, Steven Gallinger
Trends in Molecular Medicine (2017) Vol. 23, Iss. 12, pp. 1121-1137
Closed Access | Times Cited: 52
Olaparib for the treatment of breast cancer
Gaia Griguolo, Maria Vittoria Dieci, Valentina Guarneri, et al.
Expert Review of Anticancer Therapy (2018) Vol. 18, Iss. 6, pp. 519-530
Closed Access | Times Cited: 52
Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib
Polly Gravells, James R. Neale, Emma K. Grant, et al.
DNA repair (2017) Vol. 61, pp. 25-36
Open Access | Times Cited: 51
Harnessing DNA Replication Stress for Novel Cancer Therapy
Huanbo Zhu, Umang Swami, Ranjan Preet, et al.
Genes (2020) Vol. 11, Iss. 9, pp. 990-990
Open Access | Times Cited: 42
PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities
Wenhao Li, Fei Wang, Gui-yuan Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells
Michelle Schacke, Janani Kumar, Nicholas Colwell, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 518-518
Open Access | Times Cited: 40
Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications
Medhavi Gupta, Renuka Iyer, Christos Fountzilas
Cancers (2019) Vol. 11, Iss. 12, pp. 1980-1980
Open Access | Times Cited: 40
Page 1 - Next Page

Scroll to top